ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

Findings from a planned interim analysis of the Ib/II Study 111 showed that lenvatinib plus pembrolizumab induced a disease control rate of 94% in patients with metastatic clear cell RCC who had disease progression following treatment with a PD-1/PD-L1 inhibitor.
Feature:

Coverage from the 18th International Kidney Cancer Symposium

 Learn More >>

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.